RxDoctor Payments Data

David Califf

Psychiatric/Mental Health · Vancouver, WANPI 1407537145

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 229 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,782, 2.2 times the $801 reported in 2023. Among psychiatric/mental health clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,158in general payments, 2019–2025

Across 229 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$737
  • Supernus Pharmaceuticals, Inc.$618
  • Teva Pharmaceuticals USA, Inc.$365
  • Alkermes, Inc.$357
  • Corium, LLC$265
  • Bausch Health US, LLC$258
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$4,156100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,158 in reported general payments places this provider in the 90th percentile of 931 psychiatric/mental health providers in Washington.

See all psychiatric/mental health providers in Washington

Medicare billing

Part B allowed, 2024
$40,067
Medicare patients
38
Services billed
460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole36$3,238
Vilazodone Hcl19$1,919
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine40$1,172
Mirtazapine48$949
Doxepin Hcl11$831
Quetiapine Fumarate ErQuetiapine Fumarate11$588
Olanzapine30$553
Lithium Carbonate ErLithium Carbonate20$553
Escitalopram Oxalate25$513
Trazodone Hcl36$511
Lamotrigine39$477
Bupropion XlBupropion Hcl17$447
Venlafaxine Hcl ErVenlafaxine Hcl23$375
Duloxetine Hcl22$294
Fluoxetine Hcl21$244

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →